Parametric Portfolio Associates LLC increased its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 20.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 174,763 shares of the company’s stock after purchasing an additional 29,484 shares during the quarter. Parametric Portfolio Associates LLC owned 0.47% of Omnicell worth $7,532,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in OMCL. Ameritas Investment Partners Inc. acquired a new position in Omnicell in the 1st quarter worth about $125,000. Oppenheimer Asset Management Inc. acquired a new position in Omnicell in the 1st quarter worth about $170,000. Turner Investments LLC acquired a new position in Omnicell in the 2nd quarter worth about $181,000. Riverhead Capital Management LLC raised its holdings in Omnicell by 76.3% in the 2nd quarter. Riverhead Capital Management LLC now owns 4,230 shares of the company’s stock worth $182,000 after purchasing an additional 1,830 shares during the period. Finally, Sei Investments Co. raised its holdings in Omnicell by 36.4% in the 2nd quarter. Sei Investments Co. now owns 4,652 shares of the company’s stock worth $200,000 after purchasing an additional 1,242 shares during the period.
Shares of Omnicell, Inc. (NASDAQ OMCL) opened at 51.30 on Wednesday. The firm’s 50-day moving average price is $50.41 and its 200 day moving average price is $45.18. Omnicell, Inc. has a 1-year low of $30.35 and a 1-year high of $52.70. The stock’s market capitalization is $1.92 billion.
Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, July 27th. The company reported $0.02 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.02. Omnicell had a negative net margin of 1.14% and a positive return on equity of 0.41%. The company had revenue of $180.90 million during the quarter, compared to the consensus estimate of $174.08 million. During the same period last year, the firm earned $0.38 EPS. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. Equities research analysts expect that Omnicell, Inc. will post $1.30 earnings per share for the current fiscal year.
A number of equities analysts recently weighed in on OMCL shares. Zacks Investment Research raised Omnicell from a “sell” rating to a “hold” rating in a report on Tuesday, July 4th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $47.00 price target on shares of Omnicell in a report on Tuesday, July 25th. Craig Hallum upped their price target on Omnicell from $46.00 to $52.00 and gave the stock a “buy” rating in a report on Friday, July 28th. Dougherty & Co upped their price target on Omnicell from $45.00 to $49.00 and gave the stock a “buy” rating in a report on Friday, July 28th. Finally, Piper Jaffray Companies reaffirmed a “hold” rating and issued a $40.00 price target on shares of Omnicell in a report on Sunday, July 30th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $51.57.
In other news, EVP Robin Gene Seim sold 15,109 shares of Omnicell stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $50.86, for a total transaction of $768,443.74. Following the completion of the sale, the executive vice president now directly owns 58,144 shares in the company, valued at approximately $2,957,203.84. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Chairman Randall A. Lipps sold 10,625 shares of Omnicell stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $52.00, for a total transaction of $552,500.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 184,094 shares of company stock valued at $9,094,791. Insiders own 3.77% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Parametric Portfolio Associates LLC Has $7.53 Million Position in Omnicell, Inc. (OMCL)” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/10/18/parametric-portfolio-associates-llc-has-7-53-million-position-in-omnicell-inc-omcl.html.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.